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Abstract
Background: Oxacillin continues to be an important agent in the treatment of staphylococcal infections; many 
generic products are available and the only requirement for their approval is demonstration of pharmaceutical 
equivalence. We tested the assumption that pharmaceutical equivalence predicts therapeutic equivalence by 
comparing 11 generics with the innovator product in terms of concentration of the active pharmaceutical ingredient 
(API), minimal inhibitory (MIC) and bactericidal concentrations (MBC), and antibacterial efficacy in the neutropenic 
mouse thigh infection model.
Methods: The API in each product was measured by a validated microbiological assay and compared by slope 
(potency) and intercept (concentration) analysis of linear regressions. MIC and MBC were determined by broth 
microdilution according to Clinical and Laboratory Standard Institute (CLSI) guidelines. For in vivo efficacy, neutropenic 
ICR mice were inoculated with a clinical strain of Staphylococcus aureus. The animals had 4.14 ± 0.18 log10 CFU/thigh 
when treatment started. Groups of 10 mice per product received a total dose ranging from 2.93 to 750 mg/kg per day 
administered q1h. Sigmoidal dose-response curves were generated by nonlinear regression fitted to Hill equation to 
compute maximum effect (Emax), slope (N), and the effective dose reaching 50% of the Emax (ED50). Based on these 
results, bacteriostatic dose (BD) and dose needed to kill the first log of bacteria (1LKD) were also determined.
Results: 4 generic products failed pharmaceutical equivalence due to significant differences in potency; however, all 
products were undistinguishable from the innovator in terms of MIC and MBC. Independently of their status with 
respect to pharmaceutical equivalence or in vitro activity, all generics failed therapeutic equivalence in vivo, displaying 
significantly lower Emax and requiring greater BD and 1LKD, or fitting to a non-sigmoidal model.
Conclusions: Pharmaceutical or in vitro equivalence did not entail therapeutic equivalence for oxacillin generic 
products, indicating that criteria for approval deserve review to include evaluation of in vivo efficacy.
Background
Penicillinase-resistant penicillins, including the isoxazolyl
penicillin oxacillin (OXA), have been the mainstay treat-
ment of β-lactamase producing Staphylococcus aureus
infections since the 1960s, although their usefulness is
nowadays reduced by the emergence and worldwide dis-
semination of methicillin-resistant strains (MRSA) [1].
The patents of these drugs expired long ago and many
generic products are currently available while the innova-
tor has abandoned production of this essential antibiotic.
The only requirement by drug regulatory agencies (DRA)
to authorize marketing of generic intravenous drugs is
the demonstration of pharmaceutical equivalence,
defined as containing identical amounts of the same
active ingredients in the same dosage form and manufac-
tured in compliance with current Good Manufacturing
Practices guidelines. Bioequivalence tests are waived, as
bioavailability of intravenous formulations is by defini-
tion 100% [2-4], and therapeutic equivalence (defined as
having the same efficacy and safety profile of the compar-
ator) is assumed from pharmaceutical equivalence with-
out further testing.
* Correspondence: omar.vesga@siu.udea.edu.co
1 Professor, Department of Pharmacology & Toxicology, University of Antioquia 
Medical School, Calle 62 # 52-59, Lab. 630 Medellín, Colombia
Full list of author information is available at the end of the articleRodriguez et al. BMC Infectious Diseases 2010, 10:153
http://www.biomedcentral.com/1471-2334/10/153
Page 2 of 12
Our aim was to challenge the assumption that pharma-
ceutical equivalence is a surrogate predictor of therapeu-
tic equivalence for generic oxacillin, comparing with the
innovator product concentration and potency of the
active pharmaceutical ingredient (API), in vitro activity,
and in vivo efficacy against a clinical strain of S. aureus in
the neutropenic mouse thigh infection model (NMTIM).
Preliminary results of this work were presented at the
44th ICAAC [5].
Methods
Bacteria, media and antibiotics
We used the wild type clinical strain S. aureus GRP-0057
for all experiments designed to determine antibacterial
efficacy; the microorganism was grown to log phase in
Mueller-Hinton broth and agar for susceptibility tests and
in Trypticase Soy broth and agar for in vivo studies (all
from Becton Dickinson, Sparks, MD, USA). We used S.
aureus ATCC 29213 as quality control strain for suscepti-
bility testing, following recommendations from Clinical
and Laboratory Standards Institute (CLSI). S. aureus
ATCC 6538p was the seeding organism on Difco® Antibi-
otic Medium 1 for microbiological assays. Antibiotics
were bought from well-reputed local drugstores and
reconstituted according to manufacturer instructions.
The products, all licensed for human use by Invima (the
Colombian DRA), included 11 oxacillin generics manu-
factured in Colombia and the innovator product (Prosta-
filina®, Bristol-Myers Squibb, Mexico). To facilitate data
illustration, we use abbreviated names taking the first 3
letters of the manufacturer. Table 1 lists studied products
and their code, maker, batches and country of manufac-
ture; the last column describes the tests performed, as not
all generic products were available at the time of every
experiment.
Microbiological assay
The concentration of API was determined by a previously
validated assay [6]. The innovator product and 9 generics
were tested simultaneously in a 36×36 cm plate originally
described by Bennett in 1966 [7]; 2 generics were not
a v a i l a b l e  a t  t h e  t i m e  o f  t h e s e  a s s a y s  ( O X A - Q I M  a n d
OXA-SER). Pharmaceutical equivalence was defined as a
generic product displaying a regression line parallel and
overlaid to that of the innovator (P > 0.05 by CFA). On
the other hand, parallel curves with significantly different
intercepts indicated the same API but at higher or lower
concentration, while lack of parallelism implied differ-
ences in potency.
In vitro activity
Following CLSI methods [8], we determined minimal
inhibitory (MIC) and bactericidal (MBC) concentrations
by broth microdilution (1-3 assays, each by duplicate) of 9
generic products, and compared them with the innovator
(gold standard) by means of the Kruskal-Wallis test. The
generic products OXA-EXP and OXA-SCA were not
available at the time of these experiments.
Neutropenic mouse thigh infection model
Eleven generic products were available for in vivo evalua-
tion, however two of them (OXA-EXP and OXA-PEN)
had to be excluded from the analysis due to contamina-
tion of the plates which altered the reliability of CFU
counts. Six-week-old specific-pathogen-free female mice
of the strain Udea:ICR(CD-1) weighing 23-27 g were ren-
dered deeply neutropenic (≤10 neutrophils/μL) by intrap-
eritoneal injections of cyclophosphamide (Cytoxan®,
Bristol-Myers Squibb Co., New Brunswick, NJ, USA) 4
days (150 mg/kg) and 1 day (100 mg/kg) before infection
[9]. Sixteen hours after the second cyclophosphamide
dose, the animals were inoculated into each thigh with 0.1
mL of a log-phased culture of S. aureus GRP-0057
adjusted to 4.0 log10 CFU/mL. Groups of 10 mice per
product received 5 different total doses ranging from no
effect to maximum effect, allocating subgroups of 2 ani-
mals to each of 2.93, 11.7, 46.9, 187.5, and 750 mg/kg per
day. To optimize the pharmacodynamic (PD) index pre-
dicting efficacy for β-lactams (time above MIC), treat-
ment was administered q1h by 0.2 mL subcutaneous
injections [10]. Two infected but untreated control mice
were sacrificed right after inoculation (-2 h), at the onset
(0 h), and at the end of therapy (24 h), when all other
(treated) mice were euthanized and their thighs dissected
under aseptic technique, homogenized, serially diluted,
plated by duplicate on solid medium, and aerobically
incubated at 37°C for 18 hours. Data were registered as
log10 CFU/g and the limit of detection was 2.0 log10 CFU/
g. To determine net antibacterial effect, the number of
CFU remaining in the thighs after 24 hours of treatment
was subtracted from the number of CFU that grew in the
thighs of control mice during the same period. The
experimental protocol was reviewed and approved by the
University of Antioquia Animal Experimentation Ethics
Committee.
Statistical analysis of in vivo data
A sigmoid dose-response model described by the Hill
equation was used to analyze and determine in vivo effi-
cacy:
where E is the net antibacterial effect (log10 CFU/g)
after 24 h of treatment, D is the oxacillin dose (mg/kg per
day), and Emax (maximum effect in log10 CFU/g), ED50
E
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(Effective Dose needed to reach 50% of the Emax) and N
(Hill's slope describing the sensitivity of the dose-effect
relationship) are the primary pharmacodynamic parame-
ters (PDP) to be calculated by least-squares nonlinear
regression [11]. When possible, we also calculated the
secondary PDP bacteriostatic dose (BD) and the dose
needed to kill the first log of bacteria (1LKD), both
expressed as mg/kg per day (SigmaPlot 10). The number
of CFU/g obtained from untreated control mice at 0 h
subtracted from that of untreated controls at 24 h repre-
sents the net bacterial growth (G) in the absence of ther-
apy, introduced as a constant in the next two equations
used to compute secondary PDP:
Table 1: Manufacturing information of oxacillin products included in the study (11 generics plus the innovator).
OXACILLIN (OXA) PRODUCTS BATCH MANUFACTURER DISTRIBUTOR PERFORMED TESTS
OXA-BMS (innovator) EL059
EG187
EF109
EF372
ED259
Bristol-Myers Squibb de Mexico. Bristol-Myers Squibb MA, MIC&MBC, NMTIM
OXA-BLA A 4602
B 4603
Vitrofarma SA, Bogota, Colombia Laboratorios Blaskov MA, MIC&MBC, NMTIM
OXA-CAR 309V1104
378V0705
Farmacologica SA, Bogota, Colombia Carlon Ltda MA, MIC&MBC, NMTIM
OXA-COL 0010202
05103
Farmacologica SA, Bogota, Colombia Colpharma Ltda MA, MIC&MBC, NMTIM
OXA-EXP* OX 
010462
Farmacologica SA Bogota, Colombia Laboratorios 
Expopharma
MA, NMTIM
OXA-MEM 110291
050239
090281
Vitrofarma SA, Bogota, Colombia Memphis Products MA, MIC&MBC, NMTIM
OXA-OPH 080267
060249
Vitrofarma SA, Bogota, Colombia Laboratorios 
Farmaceuticos 
Ophalac
MA, MIC&MBC, NMTIM
OXA-PEN* 20275
30417
Farmacologica SA, Bogota, Colombia Pentacoop SA MA, MIC&MBC, NMTIM
OXA-QIM 6400702 Vitrofarma SA, Bogota, Colombia Quimicol MIC&MBC, NMTIM
OXA-SCA OX-
010462
Farmacologica SA, Bogota, Colombia Farmionni Scalpi S.A. MA, NMTIM
OXA-SER OX-
010508
Farmacologica SA Bogota, Colombia Serpharma SA MIC&MBC, NMTIM
OXA-VIT 120198
090281
110291
Vitrofarma SA, Bogota, Colombia Vitalis MA, MIC&MBC, NMTIM
Abbreviators: MA: microbiological assay; MIC&MBC: minimal inhibitory concentration and minimal bactericidal concentration; NMTIM: 
neutropenic mouse thigh infection model. *The data from one experiment involving these two generic products and the innovator had to be 
excluded from the analysis due to heavy contamination of agar plates containing thigh homogenates that prevented reliable colony countingRodriguez et al. BMC Infectious Diseases 2010, 10:153
http://www.biomedcentral.com/1471-2334/10/153
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PDP obtained for each generic product were compared
against those of the innovator by the overall test for coin-
cidence of nonlinear regression (Prism 5, GraphPad Soft-
ware). Accepting a 5% chance for a type I error, the
treatment of 10 animals per product to compare 9 generic
products with the innovator oxacillin confers 87.3%
power to reject the null hypothesis if the magnitude of
the difference in antibacterial efficacy is ≥1.0 log10 CFU/g
and the standard deviation (SD) is <0.5 log10 CFU/g. Such
difference between generics and the innovator represents
a net bactericidal effect greater than 100,000 bacterial
cells per gram of tissue, a threshold value several orders
of magnitude greater than what would be considered
important in clinical medicine.
Instead of the expected sigmoid Hill's pharmacody-
namic pattern, one product displayed a U-shaped dose-
effect curve. The best fit for such pattern is the Gaussian
model, as described by Christopoulos for compounds
with simultaneous agonistic and antagonistic actions
[11]:
where
Basal represents response in the absence of antibiotic,
Range is the maximal inhibitory response value lying
within the Basal and the deepest point of the Gaussian
curve (Emax - Basal), and Slope is a fitting constant that
describes the particular form of the bell-shaped curve
(should not be confused with Hill's slope) [12]. LogED50 is
the logarithm of the effective dose needed to reach 50% of
the Emax. The expression 10log[A] in Equation 4 corre-
sponds to the logarithmic form in which the dose is intro-
duced in all dose-response relationships: [A] is the
independent variable, represented here by the 24 h total
dose. Since Basal is zero (CFU/gcontrols - CFU/gtreated = 0
without treatment), Range equals Emax in our Gaussian
model, therefore
If generic and innovator fit different pharmacodynamic
models, they are not therapeutically equivalent by defini-
tion: the World Health Organization defines two prod-
ucts as therapeutically equivalent "if they are
pharmaceutically equivalent and, after administration in
the same molar dose, their effects with respect to both
efficacy and safety are essentially the same, as deter-
mined from appropriate bioequivalence, pharmacody-
namic,  c l i n i c a l  o r  i n  v i t r o  s t u d i e s "  ( b o l d  b y  u s ) .  T o
establish which model more appropriately described the
dose-effect relationship of each oxacillin product, we ran
their respective NLR under both models, and then com-
puted the probability of each model by corrected Akaike's
Information Criteria with Prism 5.
In addition, we ran all products simultaneously under
Hill's model (multiple NLR, M-NLR) fixing Emax to the
value of the innovator, which permits calculation of hypo-
thetical ED50 and N values for generic products "forced"
to reach the innovator's efficacy, as clinicians try by
increasing the dose of generics. The null hypothesis
(generic product = innovator product) and our experi-
mental design (simultaneous evaluation of generic and
innovator) allow this M-NLR approach which, by giving
PDP for all products without violating NLR assumptions,
validates an alternative comparison by CFA with all prod-
ucts under Hill model.
Results
Microbiological assay
Panel A of Figure 1 shows the standard curves generated
by linear regression of innovator oxacillin and 5 generic
products that demonstrated pharmaceutical equivalence
(i.e. without significant differences in slope neither inter-
cept with respect to the innovator); all data belong to the
same population and therefore are best fitted by a single
linear regression. These products were OXA-BLA, OXA-
COL, OXA-OPH, OXA-PEN, and OXA-SCA, and their
relative potencies ranged between 96.9 and 100.6% with
respect to the innovator.
Panel B of Figure 1 displays the regression lines of inno-
vator oxacillin and 4 generics that exhibited statistically
significant differences in slope (OXA-CAR, OXA-EXP,
OXA-MEM, and OXA-VIT; P < 0.03458), indicating
pharmaceutical inequivalence due to alterations in the
potency of their API (these 4 generics belong to popula-
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tions different to that of the innovator product, therefore
each is fitted with its own regression). Relative potency of
these 4 products was 85.6, 92.4, 95.3, and 94.0%, respec-
tively. OXA-CAR (batch 378v0705) was the only product
which did not dissolve completely, in accordance with a
grossly different standard curve (Figure 1, panel B). For
subsequent experiments with OXA-CAR different
ampoules without dissolution problems were used (batch
309v1104).
In vitro activity
Table 2 presents the MIC, MBC and MBC/MIC ratio of
the innovator and 9 generic products of oxacillin against
S. aureus ATCC 29213 and S. aureus GRP-0057.There
were no differences with the innovator, including the
products lacking pharmaceutical equivalence (see Dis-
cussion).
Neutropenic mouse thigh infection model
A total of 4 technically valid in vivo experiments compar-
ing the innovator with generic products were performed.
Table 3 shows the bacterial loads in untreated controls at
0 and 24 h (when oxacillin was started and ended, respec-
tively, in the treatment groups), and the net growths
achieved. To test the reproducibility of the animal model,
we compared by CFA the 4 dose-response curves
obtained from these experiments for the innovator prod-
uct OXA-BMS (Figure 2), and showed that all data sets
were best described by 1 rather than 4 separate regression
lines (P = 0.4396), indicating that all data in the innova-
tor's NLR came from the same population. One addi-
tional experiment comparing OXA-BMS, OXA-EXP and
OXA-PEN was excluded from the analysis because it was
heavily contaminated with Gram-negative bacilli that
altered S. aureus colony counting and generated falsely
higher antibacterial effects for all products.
Figure 3 and Table 4 show the dose-response relation-
ships and magnitudes of the PDP obtained by NLR for 9
oxacillin generic products and the innovator from the
four combined in vivo experiments. All generics failed to
reach the innovator's maximum effect regardless their
pharmaceutical equivalence: the most and least effective
products killed 22- and 1585-fold fewer microorganisms
per gram of tissue respectively than OXA-BMS. In vivo
potency of generic products was also significantly infe-
rior: OXA-CAR and OXA-COL required respectively
1.57- and 2.13-fold higher dose for bacteriostasis com-
pared with the innovator (BD = 62.2 mg/kg), other 6
products did not reach enough efficacy to calculate their
BD (i.e., their maximum effect was lower than the bacte-
rial growth in control animals), one (OXA-SER) did not
fit to Hill's model, and no one killed enough bacteria to
calculate their 1LKD (it was 108.4 mg/kg per day for
OXA-BMS). Tables 4 and 5 show that in all cases where
secondary PDP could not be computed due to lack of effi-
cacy, the only accurate conclusion is that the magnitude
of the PDP is greater than the maximum dose used in
vivo (750 mg/kg per day).
Using Akaike's Information Criteria, we demonstrated
a different pharmacodynamic pattern for OXA-SER, the
only product in which greater doses killed fewer bacteria
(Eagle effect). The probability of the model being correct
Figure 1 Concentration-response relationship of innovator and generic products of oxacillin in the microbiological assay. A. The slopes and 
intercepts of OXA-BLA, OXA-COL, OXA-OPH, OXA-PEN, and OXA-SCA were not statistically different from those of OXA-BMS (innovator), thus confirm-
ing their pharmaceutical equivalence (P = 0.1165). The standard curves of all products are better described by a single linear regression, shown here 
with the 95% confidence interval. B. The slopes and intercepts of OXA-CAR, OXA-EXP, OXA-MEM and OXA-VIT were significantly different to the inno-
vator's (P < 0.03458), thus failing pharmaceutical equivalence. As generic products belong to populations different to that of the innovator, each is 
described by an independent linear regression with their respective coefficient of determination (r2).Rodriguez et al. BMC Infectious Diseases 2010, 10:153
http://www.biomedcentral.com/1471-2334/10/153
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Table 2: In vitro activity of 9 generic products of oxacillin and the innovator against two strains of S. aureus.
OXACILLIN (OXA) PRODUCTS S. aureus ATCC 29213 S. aureus GRP-0057
MIC (mg/L) MBC (mg/L) MBC/MIC Ratio MIC (mg/L) MBC (mg/L) MBC/MIC Ratio
OXA-BMS (innovator) 0.22 0.40 1.78 0.16 0.25 1.59
OXA-BLA 0.50 0.50 1.00 0.18 0.50 2.83
OXA-CAR 0.50 1.00 2.00 0.50 0.50 1.00
OXA-COL 0.50 0.71 1.41 0.18 0.35 2.00
OXA-MEM 0.13 0.13 1.00 0.13 0.13 1.00
OXA-OPH 0.25 0.71 2.83 0.18 0.25 1.41
OXA-PEN 0.25 0.35 1.41 0.18 0.21 1.19
OXA-QIM 0.50 1.00 2.00 0.18 0.25 1.41
OXA-SER 0.25 0.50 2.00 0.25 0.50 2.00
OXA-VIT 0.13 0.13 1.00 0.13 0.13 1.00
Exact P (KW*) 0.2115 0.2110 0.2611 0.3650 0.1339 0.2751
Values represent geometric means of each MIC, MBC and MBC/MIC ratio, obtained from 1 to 3 duplicate determinations (ranges not included for 
brevity and clarity). * Kruskal-Wallis test.
Table 3: Bacterial loads and net growths in untreated control mice at the beginning and end of treatment.
EXPERIMENT Bacterial Load at 0 h (log10 CFU/g) Bacterial Load at 24 h (log10 CFU/g) Net Growth G 
(log10 CFU/g)
Mean SD Mean SD
1 3.96 0.035 7.86 0.011 3.90
2 4.09 0.106 7.48 0.269 3.39
3 3.85 0.007 7.29 0.347 3.44
4 4.66 0.070 7.57 0.004 2.91
Mean ± SEM 4.14 ± 0.180 7.55 ± 0.119 3.41 ± 0.202Rodriguez et al. BMC Infectious Diseases 2010, 10:153
http://www.biomedcentral.com/1471-2334/10/153
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was 92.5% for the Gaussian and 7.52% for the Hill model,
therefore the former was adopted: Emax = -5.1 log10
CFU/g, logEC50 = 1.78, EC50 = 60.3 mg/kg per day, slope
= 0.87 (data shown in Table 4 includes only OXA prod-
ucts fitting Hill's model).
Table 5 shows results from multivariate nonlinear
regression (M-NLR) under Hill's model (this precluded
the use of OXA-SER). In order to fulfill the regression
requirements of normality and homoscedasticity, each
experiment was analyzed separately. As explained under
Methods, fixing the Emax to the value reached by OXA-
BMS creates a hypothetical situation where all products
are as effective as the innovator and allows calculation of
their true potency in vivo. M-NLR demonstrated that
generic products would have needed 3.33-15.2 and 2.38-
8.48 greater doses to attain bacteriostasis (BD) and to kill
the first log (1LKD), respectively. OXA-OPH generated
invalid BD and 1LKD parameters (i.e., not statistically dif-
ferent from zero) due to extremely poor effects, and all
but 3 generics (OXA-CAR, OXA-QIM and OXA-COL)
generated invalid 1LKD.
Discussion
These data demonstrate that generic products of oxacillin
lack therapeutic equivalence in an animal model, despite
the fact that 5 of 9 displayed pharmaceutical equivalence
in a validated microbiological assay. The other 4 products
did differ in potency, manifested by the divergent slopes
of their standard curves compared with the innovator.
This finding suggests that the molecules were not identi-
cal to the comparator and that subtle alterations, due to
possible structural differences, spatial orientation, and/or
impurities, might have affected their antibacterial activity
in the microbiological assay and, therefore, in vivo [13].
Figure 2 Dose-response relationship of innovator oxacillin (OXA-BMS) in 4 independent experiments in the neutropenic mouse thigh in-
fection model, fitted to Hill's model by NLR. The four experiments (gray lines) were indistinguishable by curve fitting analysis (CFA), thus a single 
regression (red curve) described them better than 4 individual regressions.Rodriguez et al. BMC Infectious Diseases 2010, 10:153
http://www.biomedcentral.com/1471-2334/10/153
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While therapeutic inequivalence of these 4 generics with
inferior potency was expected and understandable, in
vivo failure of the 5 products that demonstrated pharma-
ceutical equivalence contradicts current assumptions
made by patients, physicians, DRA and the World Health
Organization (WHO) [13-17].
All generics had lower ED50 than the innovator OXA,
showing a seemingly greater potency. It is in fact appar-
ent, because the PDP potency (ED50) is relative to the
compound's efficacy (Emax), which was 22 to 1585-fold
lower than the innovator's. This difference in potency
disappears when secondary PDP are computed. These
parameters convey more biological sense to the clinician
because they are based on the amount of drug needed to
reach measurable bacteriostatic and bactericidal effects
for the bacterial load and growth suffered by the animal
during the experiment. As shown in Table 4, OXA-CAR
and OXA-COL required 1.57 and 2.12-times greater
amount of drug to reach the BD while it could not be cal-
culated for the other products because either they failed
to kill at least 3.4 log10 CFU/g of bacteria (average growth
in controls) or did not fit to Hill's model (OXA-SER).
Notably, no generic reached 1LKD (i.e. a reduction of at
least 4.4 log10 CFU/g compared to controls). This fact is
further demonstrated with the multiple NLR (Table 5), in
which, after equating efficacy (Emax), all generics require
higher ED50, BD and 1LKD. It means that, assuming that
generics were as effective as the innovator product, all are
significantly less potent independently of the PDP used.
As explained in Methods, oxacillin products were pur-
chased on demand and it was not possible to obtain iden-
tical batches of each product for both in vitro and in vivo
testing. To make sure that failure was batch-independent,
the design included at least 2 batches per product (if
available), and so one batch was studied both in vitro and
vivo, and the other(s) in vitro or in vivo (Table 1). As a
result, we allocated the same batch of the innovator and 6
generics to MIC, MBC and in vivo experiments, and the
same batch of the other 5 generics to microbiological
assays and in vivo experiments. Since no product failed
susceptibility tests (5 of 9 had the same batch studied in
the animal model), 4 failed in microbiological assays (2
Table 4: In vivo pharmacodynamic parameters of generic and innovator products of oxacillin by nonlinear regression 
from 4 independent experiments.
OXACILLIN 
(OXA) 
PRODUCTS
Emax (log10 CFU/g) SEM N SEM ED50 
(mg/kg)
SEM BD (mg/kg) SEM 1 LKD 
(mg/kg)
SEM Adj. R2 Sy|x P (CFA)
OXA-BMS 
(innovator)
5.42 0.08 1.73 0.13 45.19 2.32 62.24 3.07 108.36 7.32 0.99 0.23 NA
OXA-BLA 3.38 0.10 3.29 0.79 19.38 2.65 >750.00 - >750.00 - 0.98 0.21 <0.0001
OXA-CAR 3.69 0.10 1.81 0.20 25.44 2.20 97.61 16.13 >750.00 - 0.99 0.17 <0.0001
OXA-COL 3.14 0.12 1.93 0.36 35.41 3.71 132.29 33.04 >750.00 - 0.98 0.20 <0.0001
OXA-MEM 3.51 0.12 2.09 0.32 23.07 2.65 >750.00 - >750.00 - 0.96 0.32 <0.0001
OXA-OPH 3.11 0.15 NS - NS - >750.00 - >750.00 - 0.96 0.31 <0.0001*
OXA-QIM 2.22 0.10 2.72 0.60 25.00 3.95 >750.00 - >750.00 - 0.96 0.20 <0.0001
OXA-SCA 3.66 0.17 2.03 0.46 19.31 3.02 >750.00 - >750.00 - 0.95 0.31 <0.0001
OXA-SER†- - - - - - - - - - - - N A
OXA-VIT 3.01 0.12 1.55 0.26 18.51 2.50 >750.00 - >750.00 - 0.97 0.20 <0.0001
Abbreviators: Emax: maximum effect; N: Hill's slope; ED50: effective dose to reach 50% of Emax; BD: bacteriostatic dose; 1LKD: 1 log kill dose; Adj. 
R2: adjusted coefficient of determination; Sy|x: standard error of the estimate; SEM: standard error of the mean; NA: not applicable; Bold numbers: 
not statistically different from zero, invalid parameter. * CFA comparison of Emax only. † Pharmacodynamic profile fits to Gaussian instead of Hill's 
model.Rodriguez et al. BMC Infectious Diseases 2010, 10:153
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had the same batch studied in the animal model), and all
generics failed in vivo (all had the same batch studied in
vitro, 6 for MIC & MBC and the other 5 for microbiologi-
cal assay), the design demonstrates that therapeutic
inequivalence is not a batch-related but a product-related
problem.
One more clarification is pertinent considering that
readers would like to know about results with products
excluded for technical reasons (OXA-EXP and OXA-
PEN, animal model) or due to unavailability at the time of
certain experiments (OXA-QIM and OXA-SER, microbi-
ological assay; OXA-EXP and OXA-SCA, susceptibility
testing). One experiment in the animal model had to be
excluded because of contamination that precluded a reli-
able bacterial count in the plates. Data from that experi-
ment involved three generic products (OXA-EXP, OXA-
PEN, OXA-VIT) and the innovator (OXA-BMS).
Although the data are not shown, it should be noted that
all generics in that experiment were significantly inferior
respect to the innovator (Emax = 4.85 ± 0.28, 4.74 ± 0.53,
3.02 ± 0.20, and 6.20 ± 0.22, respectively; P < 0.0001 by
CFA). Regarding unavailable products, no conclusion can
be made about pharmaceutical equivalence of OXA-QIM
and OXA-SER, but both failed in vivo (please see further
discussion about the last product below). OXA-SCA
lacked MIC and MBC data, its potency and concentra-
tion were undistinguishable from the innovator, but failed
in vivo too. Results with the other products suggest that
standard susceptibility testing cannot detect differences
among pharmaceutically and/or therapeutically inequiva-
lent generics, which is explained by the very low power of
this in vitro method in comparison with the microbiolog-
ical assay (7.1% versus 98.9%, calculated with Sigma Plot
10.0 and StudySize 2.0).
Figure 3 Dose-response relationship of the innovator and 9 generic products of oxacillin in the neutropenic mouse thigh infection model. 
OXA-BMS (innovator, black curve) and 8 generics fitted to Hill's sigmoid model, while generic product OXA-SER fitted to the Gaussian U-shaped model 
(red curve). Regardless of pharmaceutical equivalence and in vitro activity, all generics displayed significantly inferior bactericidal efficacy (P < 0.0001) 
or different pharmacodynamic behavior (Gaussian instead of sigmoid) compared with the innovator, thus lacking therapeutic equivalence.Rodriguez et al. BMC Infectious Diseases 2010, 10:153
http://www.biomedcentral.com/1471-2334/10/153
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The Eagle effect displayed by OXA-SER explains its
Gaussian pharmacodynamic pattern (Figure 3), described
at the beginnings of the antibiotic era for penicillins and
later for other antibacterials [18]. This case was unique
among oxacillin generics; OXA-SER probably had degra-
dation products in its formulation that competed with
the API for the molecular target, as we described recently
with generics of vancomycin [19].
The other 8 generics had pharmacodynamic profiles
fitting to Hill's model, but with markedly inferior efficacy;
although several reasons could potentially explain their
failure, the fact that it was detected only in vivo suggests
that these compounds change when their targets (bacte-
ria) are located in tissues instead of culture media. Oxa-
cillin is the most unstable isoxazolyl penicillin: it starts
degrading as soon as entering the body, to the point that
Table 5: In vivo pharmacodynamic parameters of oxacillin products by multiple nonlinear regression (M-NLR).
OXACILLIN (OXA) PRODUCTS N SEM ED50 (mg/kg) SEM BD (mg/kg) SEM 1LKD (mg/kg) SEM
Experiment 1
OXA-BMS (innovator) 1.73 0.30 45.13 5.47 77.73 0.20 104.79 24.18
OXA-OPH 0.47 0.09 95.15 35.54 >750.00 - >750.00 -
OXA-MEM 0.56 0.10 76.42 24.90 409.36 182.35 >750.00 -
OXA-SCA 0.56 0.10 72.66 23.71 390.13 172.68 >750.00 -
OXA-VIT 0.45 0.10 205.11 84.98 750.00* 373.73 >750.00 -
Experiment 2
OXA-BMS (innovator) 1.73 0.18 45.13 3.33 60.71 4.33 96.48 12.24
OXA-CAR 0.64 0.07 90.52 16.50 202.51 39.36 230.84 230.84
Experiment 3
OXA-BMS (innovator) 1.73 0.29 45.13 5.39 62.17 7.07 97.35 20.07
OXA-MEM 0.63 0.12 127.53 38.29 307.47 101.82 >750.00 -
OXA-OPH 0.55 0.10 128.00 42.18 526.98 225.98 >750.00 -
OXA-BLA 0.59 0.11 101.00 31.58 259.22 88.45 >750.00 -
Experiment 4
OXA-BMS (innovator) 1.73 0.21 45.13 3.96 49.23 3.83 88.41 17.53
OXA-QUIM 0.40 0.08 750.00 321.55 750.00* 287.80 750.00* 327.88
OXA-COL 0.58 0.09 221.34 54.59 287.58 70.52 750.00* 356.95
Under this analysis, maximum effect (Emax) for all products is fixed to the innovator's (Emax= 5.42 log10 CFU/g).
Abbreviators: N: Hill's slope; ED50: effective dose to reach 50% of Emax; BD: bacteriostatic dose; 1LKD: 1 log kill dose; SEM: standard error of the 
mean; Bold numbers: not statistically different from zero, invalid parameter. * Maximum dose used in the experiments.Rodriguez et al. BMC Infectious Diseases 2010, 10:153
http://www.biomedcentral.com/1471-2334/10/153
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by 12 h half of the drug has been eliminated as penicilloic
acid in healthy subjects [20]. Instability has already been
reported as the cause of therapeutic failure with a generic
product of the betalactam cefuroxime [21]. There is evi-
dence that oxacillin's resistance to bacterial beta-lactama-
ses depends on the relative rigidity of the 6 β-side chain
and the nature and orientation of substituents beyond the
6 β-amide carbonyl group [22]. Biochemical conditions
affect these molecular interactions, and many biody-
namic variables occur in the live animal that are absent in
v i t r o ,  p a r t i c u l a r l y  i n  s t a n d a r d i z e d  t e s t s  l i k e  t h o s e
employed to detect pharmaceutical equivalence or sus-
ceptibility to antimicrobials. The lack of one or both of
the above mentioned characteristics in the site of infec-
t i o n  ( c a u s e d  b y  a n  u n s t a b l e  A P I  o r  b y  l e s s - t h a n - i d e a l
excipients) could also generate a poor target for PBP2,
explaining in vivo failure of generic oxacillin. To test this
hypothesis, one could compare the spatial coordinates of
generic products with those of the innovator, as well as
their crystal structures and conformational energy maps
in culture media and in infected tissues [23].
We found no studies regarding generic products of oxa-
cillin. It is not surprising because (1) nobody has looked
so far into therapeutic equivalence of generic medicines
in general, and (2) the innovator of oxacillin abandoned
its product several years ago. An entire society (like
Colombian People) without therapeutically equivalent
oxacillin is a highly dangerous consequence derived from
the usual strategy taken by innovator pharmaceutical
industry (to abandon the product) to evade the insur-
mountable competition represented by inexpensive, often
ludicrously cheap generic products. The interest of big
pharma in creating marketing niches for their new, very
expensive compounds (free of generic competition) is
generating a second consequence involving many old (but
critically important) antibiotics. The industry must dem-
onstrate to DRA that their new compounds have any
advantage at all compared with the old, reliable, inexpen-
sive antimicrobials. If one looks carefully at these cam-
paigns, virtually all clinical trials compare the new
compound against well-established drugs such as vanco-
mycin or oxacillin, but without identifying their maker. It
is not uncommon for the new drug to end the winner, but
one wonders how many of these research subjects were
treated with the innovator of vancomycin or oxacillin,
and how many with inequivalent generics from multiple
sources.
The consequences of prescribing generic oxacillin
devoid of therapeutic equivalence are indeed serious, and
affect more people than the sick individual receiving the
drug. Patients with non-lethal but serious staphylococcal
infections would take longer to get better, increasing the
costs of their care and the probability of nosocomial
infections or sequelae from the poorly treated staphylo-
coccal infection. Those with life-threatening infections
are at risk of dying due to ineffective therapy, but it might
pass unnoticed by the physician, who could attribute
death to an inevitable bad prognosis. One million bugs
per gram of tissue left alive by the failing generic could
increase its chances of selecting resistant mutants, mak-
ing resistance a theoretical possibility [24]. It would be
the most concerning consequence of massive use of phar-
maceutically equivalent but therapeutically inequivalent
generic antibiotics. Our current research points to that
direction [25].
Conclusions
Pharmaceutical equivalence or similar MIC & MBC val-
ues of any generic product of oxacillin are not useful cri-
teria for granting therapeutic equivalence. In order to do
it, all generic products of oxacillin should be tested in
vivo. Otherwise, clinicians would expose patients to an
unacceptable risk of treatment failure, especially immu-
nosuppressed and critically ill patients who rely almost
completely on antibiotic efficacy for cure. The WHO and
DRA should think again this delicate issue; thorough
demonstration of therapeutic equivalence must be
required from generic makers as the case of oxacillin is
not unique [26]. Serious commitment to improve global
health, demonstrated by keeping their support for old
and inexpensive antimicrobials like oxacillin, would be
the minimum to ask from innovators.
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